ArticleACS omega2025
Urinary IR700 Ligand as an Early Biomarker of Therapeutic Efficacy of Near-Infrared Photoimmunotherapy.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Near Infrared Photoimmunotherapy for Lung Cancer: Recent Development and Perspective.ImmunoTargets and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Near-infrared photoimmunotherapy (NIR-PIT) is a cell-selective cancer therapy employing monoclonal antibody-photoabsorber conjugates (APCs) and near-infrared (NIR) light. When exposed to NIR light, the photoabsorber, IR700, releases an axial ligand, resulting in a transition of the remaining molecule from water-soluble to hydrophobic. This results in the death of APC-bound cells by physical damage to the cell membrane. The amount of released IR700 ligand reflects the completeness of the photochemical reaction and, therefore, can be a biomarker for treatment efficacy. In this study, we developed and validated a quantitative analytic method for detecting excreted IR700 ligands in urine using a liquid chromatograph-triple quadrupole mass spectrometer (LC-MS/MS). In A431 tumor-bearing mice treated with NIR-PIT, the urinary ligand increased with increasing the light dose, which was positively correlated with the loss of fluorescence and therapeutic effects. This study suggests that quantitative analysis of urinary ligands using LC-MS/MS can be a rapid biomarker of NIR-PIT efficacy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.